Detection And Clinical Significance Of Plasma Urokinase-type Plasminogen Activator And Its Soluble Receptor In Multiple Myeloma Patients

Objective To study the changes of plasma urokinase-type plasminogen activator(u-PA) and its soluble receptor(suPAR )in multiple myeloma(MM) patients for evaluating their clinical significance. Methods Plasma u-PA and suPAR levels in 34 MM cases were measured by enzyme-linked immunosorbent assay(ELISA),the changes of plasma u-PA and suPAR levels in 6 MM cases were simultaneously observed before and after chemotherapy. Results The plasma u-PA and suPAR levels in evolution period of MM patients were significantly higher than that in stable period of MM patients and in normal control (.PO.01) ,whereas, there were no obvious difference between stable period of MM patients and normal control (/*>0.05) .Among 6 cases, The plasma u-PA and suPAR levels after chemotherapy were significantly lower than that before chemotherapy (P<0.05) . The plasma u-PA and suPAR levels were significantly higher in MM patients with more tumorcells(>20%)than with less tumor cells(D20%)(/)<0.05 ; /><0.01).The plasma u-PA and suPAR levels were positively correlated with the levels of serum globulin and the percentage of bone marrow tumor cells, but negatively correlated with the levels of serum albumin. Conclusion The rise of plasma u-PA and suPAR levels may be closely associated with the occurrence and development of multiple myeloma. Plasma u-PA and suPAR levels can be served as an important index for judging the effect of treatment and clinical stage and for assessing MM progression and patient's prognosis.